LEP and metabolic dysfunction-associated steatotic liver disease: A study verified no significant differences in adiponectin and leptin levels in the dapagliflozin-treated group compared to the placebo group [157], whereas the lower serum level of high-molecular-weight adiponectin was correlated with an improved response to dapagliflozin in T2DM patients with NAFLD [156].